NEOIMMUNETECH, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,770 KRW | -4.48% |
|
-7.28% | -12.59% |
| Apr. 02 | NeoImmuneTech, Inc. Announces Chief Executive Officer Changes | CI |
| Jan. 15 | NeoImmuneTech, Inc. Appoints Luke Oh as President | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 203,671 | 78,963 | 40,041 |
| Enterprise Value (EV) 1 | 54,995 | -33,261 | -25,123 |
| P/E ratio | -18.8 x | -6.53 x | -3.75 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -1.1 x | 0.6 x | 0.48 x |
| EV / FCF | -2.15 x | 1.15 x | 0.65 x |
| FCF Yield | -46.5% | 86.8% | 153% |
| Price to Book | 31.5 x | 16.5 x | 13.4 x |
| Nbr of stocks (in thousands) | 19,678 | 19,765 | 19,773 |
| Reference price 2 | 10,350 | 3,995 | 2,025 |
| Announcement Date | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | -30,282 | -50,033 | -55,380 | -52,637 |
| EBIT 1 | -31,270 | -51,906 | -58,182 | -55,847 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -30,429 | -52,413 | -60,289 | -53,303 |
| Net income 1 | -30,456 | -52,482 | -60,406 | -53,405 |
| Net margin | - | - | - | - |
| EPS 2 | -368.5 | -550.9 | -611.6 | -540.3 |
| Free Cash Flow 1 | -21,632 | -25,579 | -28,855 | -38,500 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/23/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 68,311 | 148,676 | 112,224 | 65,164 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -21,632 | -25,579 | -28,855 | -38,500 |
| ROE (net income / shareholders' equity) | -30.4% | -42.6% | -42.9% | -54.9% |
| ROA (Net income/ Total Assets) | -18% | -23% | -22.2% | -30.3% |
| Assets 1 | 169,016 | 228,649 | 271,509 | 176,242 |
| Book Value Per Share 2 | 204.0 | 329.0 | 242.0 | 151.0 |
| Cash Flow per Share 2 | 172.0 | 313.0 | 234.0 | 139.0 |
| Capex 1 | 1,087 | 2,710 | 2,477 | 791 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/23/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.59% | 25.31M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A950220 Stock
- Financials NeoImmuneTech, Inc.
